Fig 1: NKp30-B7H6 interaction and tumour-derived PGD2 favour IL-13 secretion. a Cytokine concentrations in serum samples of HD and APL patients (APL) (n = 11). b Representative examples of flow cytometry analysis of cytokine production by ILC in HD and APL patients (APL). c Frequencies of cytokine producing ILC in HD and APL patients (APL), upon co-culture with APL cell lines for 48 h (six independent experiments). d Representative example of flow cytometry analysis of IL-13-positive cells upon co-culture with autologous APL blasts. e Frequencies of IL-13+ ILC2, NKT and Th2 cells (n = 6). f Expression of B7H6 and g frequency of B7H6-positive cells in APL cell lines (NB4, HL60) and a control cell line (721.221, lymhphoblastoid cell line) (six independent experiments). h Representative example of flow cytometry analysis of the expression of B7H6 and i frequency of B7H6-positive cells in APL blasts in bone marrow (APL BM), in APL blasts in peripheral blood (APL PB), (n = 11) or in a control cell line (721.221, n = 6). j Representative example of flow cytometry analysis of the expression of NKp30 on ILC2 in peripheral blood of healthy donors (HD PB), in APL BM or in APL PB. k Relative frequencies of NKp30 expressing ILC2 in HD PB, APL BM or APL PB (n = 11). l Representative example of flow cytometry analysis of IL-13 produced by ILC2 co-cultured with the APL cell line NB4 in the presence of an anti-NKp30 blocking antibody (aNKp30), Ig control or medium. m Frequency of ILC2 IL-13+ in medium (n = 9), in the presence of an aNKp30 or an Ig control (IgM Ctrl) (n = 6, three independent experiments). n Quantification of IL-33, IL-25, TSLP and PGD2 in the sera of HD and APL patients (APL) (n = 11). o Quantification of PGD2 in supernatants of leukaemic AML (KG1, THP1) and APL cell lines (NB4, HL60), in the absence or presence of arachidonic acid (ArAc) (1 experiment). Error bars are s.e.m. Statistical analysis was performed using Mann-Whitney test (a–c, n) and Kruskal-Wallis test (d–i, m) and ANOVA test (k)